A 2019 randomized controlled trial in *Nutrition & Metabolism* found that allulose consumption led to a 23% lower postprandial glucose response compared to sucrose in overweight adults
Common Ingredients in Fat Burners Caffeine (high doses) Green tea extract Yohimbine Synephrine Capsaicin Appetite suppressants These ingredients act quicklybut not always gently
Molecular mechanisms and clinical applications of angiogenesis
Food and Drug Administration (FDA) approved Novo Nordisks Wegovy for chronic weight management
Supplements to Decrease Melanin Production in Skin For individuals exploring supplements to decrease melanin production in skin, certain vitamins and antioxidants offer a safe and effective way to achieve a more even complexion and reduce hyperpigmentation
May 27, 2026, 09:00 ET Phase 3 REIMAGINE 13 trial results across a range of type 2 diabetes patient groups offer further insight into CagriSema, a novel amylin RA and a GLP-1 RA in a fixed-dose combination 1 Mid-stage trial data for investigational zenagamtide explore the safety and efficacy of the injectable formulation of the novel GLP-1/amylin-based treatment 2 New Ozempic and Wegovy data provide further evidence of semaglutide's strong cardiometabolic profile PLAINSBORO, NJ and BAGSVRD, Denmark, May 27, 2026 /PRNewswire/ -- Novo Nordisk today announced that new data from its cardiometabolic portfolio and pipeline will be showcased at the upcoming 2026 Scientific Sessions of the American Diabetes Association (ADA), taking place in New Orleans, June 58, 2026
